# InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Trial

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that the FDA has cleared its Investigational New Drug application to begin a Phase 2 trial of TNX-2900, a proprietary magnesium-potentiated intranasal oxytocin formulation for Prader-Willi syndrome (PWS), a rare genetic disorder and leading cause of life-threatening childhood obesity; the program has received Orphan Drug and Rare Pediatric Disease designations, making Tonix eligible for a transferable Priority Review Voucher upon approval.

 To view the full press release, visit https://ibn.fm/AP5OW

 About Tonix Pharmaceuticals Holding Corp.

 Tonix Pharmaceuticals is a commercial-stage, fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix recently received FDA approval for Tonmya (TM) , a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology and infectious diseases. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

 * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

 This press release and further information about Tonix can be found at www.tonixpharma.com .

 NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-tonix-pharmaceuticals-holding-corp-nasdaq-tnxp-advances-tnx-2900-for-prader-willi-syndrome-into-phase-2-trial/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/tonix-pharma-s-tnx-2900-cleared-for-phase-2-trial-in-rare-childhood-disorder/79989a4157e6f30a01dcc29c36305d06) 


Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202509/239286-faq-tonix-pharmaceuticals-tnx-2900-phase-2-trial-for-prader-willi-syndrome)

Pickup - [https://burstable.news/news](https://burstable.news/news/202509/239334-tonix-pharmaceuticals-advances-tnx-2900-for-prader-willi-syndrome-into-phase-2-clinical-trial)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202509/239342-tonix-pharmaceuticals-avanza-con-tnx-2900-para-el-sindrome-de-prader-willi-hacia-ensayo-de-fase-2)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202509/239476-tonix-pharmaceuticals-erhalt-fda-freigabe-fur-phase-2-studie-mit-tnx-2900-bei-prader-willi-syndrom)

Pickup - [https://actueclair.com](https://actueclair.com/202509/239448-tonix-pharmaceuticals-progresse-avec-tnx-2900-pour-le-syndrome-de-prader-willi-vers-un-essai-de-phase-2)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/30/yawniDzn.webp)